SEC Form 4 · accession 0000914190-17-000271
REGENERX BIOPHARMACEUTICALS INC · RGRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
J J Finkelstein
Officer — President and CEO · Director
Period of report
Sep 1, 2017
Accepted (ET)
Sep 6, 2017 · 4:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000707511
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 1,388,188 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $0.28 | Sep 1, 2017 | A | 150,000 | A | — | Sep 1, 2027 | Common Stock | 150,000 | 150,000 | D |
Explanation of responses
- F1The option vests in four equal annual installments beginning on September 1, 2017.